Dobutamine Stress Echocardiography for the Assessment of Pressure-Flow Relationships of the Pulmonary Circulation

Size: px
Start display at page:

Download "Dobutamine Stress Echocardiography for the Assessment of Pressure-Flow Relationships of the Pulmonary Circulation"

Transcription

1 [ Original Research Pulmonary Vascular Disease ] Dobutamine Stress Echocardiography for the Assessment of Pressure-Flow Relationships of the Pulmonary Circulation Edmund M. T. Lau, MD, FCCP ; Rebecca R. Vanderpool, PhD ; Preeti Choudhary, MD ; Lisa R. Simmons, PhD ; Tamera J. Corte, PhD ; Paola Argiento, MD ; Michele D Alto, MD ; Robert Naeije, PhD ; and David S. Celermajer, PhD BACKGROUND: Stress testing of the pulmonary circulation (via increasing pulmonary blood flow) can reveal abnormal mean pulmonary artery pressure-cardiac output (mppa-q) responses, which may facilitate early diagnosis of pulmonary vascular disease. We investigated the application of dobutamine stress echocardiography (DSE) for the noninvasive assessment of mppa-q relationships. METHODS: DSE using an incremental dose protocol ( 20 m g/kg/min) was performed in 38 subjects (16 patients with pulmonary arterial hypertension [PAH] and 22 healthy control subjects). An additional 22 healthy control subjects underwent exercise stress echocardiography as a comparator group. Multipoint mppa-q plots were analyzed, and the pulmonary vascular distensibility coefficient a was calculated. RESULTS: DSE was feasible and informative in 93% of subjects. The average dobutamineinduced mppa-q slope was mm Hg/L/min in healthy control subjects and mm Hg/L/min in patients with PAH ( P,.001). The dobutamine-induced a was markedly reduced in patients with PAH ( mm Hg vs mm Hg in control subjects, P,.001). When exercise and dobutamine stress were compared in healthy control subjects, the exercise-induced mppa-q slope was modestly higher ( mm Hg/L/min, P 5.03 vs dobutamine). In patients with PAH, lower functional class status was associated with lower dobutamine-induced mppa-q slopes ( P 5.014), but not with resting total pulmonary vascular resistance. CONCLUSIONS: Noninvasive assessment of mppa-q relationships is feasible with dobutamine stress. DSE may potentially be a useful noninvasive technique for stress testing of the pulmonary vasculature. CHEST 2014; 146(4): Manuscript received October 7, 2013 ; revision accepted February 10, 2014; originally published Online First March 13, ABBREVIATIONS: DSE 5 dobutamine stress echocardiography; HR 5 heart rate; mppa 5 mean pulmonary artery pressure; PAH 5 pulmonary arterial hypertension; PH 5 pulmonary hypertension; Pla 5 left atrial pressure; Ppa 5 pulmonary artery pressure; Q 5 cardiac output; TPVR 5 total pulmonary vascular resistance AFFILIATIONS: From the Discipline of Medicine (Drs Lau, Choudhary, Corte, and Celermajer), Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Department of Respiratory Medicine (Drs Lau and Corte), Department of Cardiology (Drs Lau, Choudhary, Simmons, and Celermajer), Royal Prince Alfred Hospital, Sydney, NSW, Australia; Department of Cardiology (Drs Argiento and D Alto), Second University of Naples, Naples, Italy; and Department of Pathophysiology (Drs Vanderpool and Naeije), Free University of Brussels, Brussels, Belgium. FUNDING/SUPPORT: This study was supported by the National Health and Medical Research Council (NHMRC) of Australia Project [Grant to Dr Celermajer and Dr Corte] and a NHMRC and Heart Foundation Postgraduate Scholarship to Dr Lau [No ]. CORRESPONDENCE TO: Edmund M. T. Lau, MD, FCCP, Department of Respiratory Medicine, Royal Prince Alfred Hospital, Missendon Rd, Camperdown, NSW 2050, Australia; edmundmtlau@gmail.com 2014 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: /chest journal.publications.chestnet.org 959

2 Stress testing of pulmonary circulation has been used for. 60 years, since the introduction of the original hemodynamic definition of pulmonary hypertension (PH). 1 The rationale was that exercise would increase cardiac output (Q) with or without an increase in left atrial pressure (Pla) and that abnormally high mean pulmonary artery pressure (mppa)-q relationships during stress could be due to an increased incremental pulmonary vascular resistance (PVR) or an increase in Pla, or both. 2 Pioneer invasive studies in healthy volunteers led to the definition of PH with an mppa. 25 mm Hg at rest and. 30 mm Hg at exercise. These cutoff values were derived with a safety margin of 4 to 5 mm Hg added to the upper limits of normal values (mppa of 20 mm Hg at rest and 25 mm Hg at exercise). 3 Exercise measurements were withdrawn from the definition of PH at the World Symposium on Pulmonary Hypertension in 2008 because of insufficient certainty about the upper limits of normal mppa at exercise and levels of symptomatic mppa. 4 Since then, there has been accumulating evidence that mppa. 30 mm Hg at exercise is actually associated with dyspnea-fatigue symptoms. 5,6 Furthermore, noninvasive and invasive exercise measurements in a large number of normal subjects have allowed better delineation of exerciseinduced PH by a mppa. 30 mm Hg at a Q, 10 L/min or slope of mppa-q relationship. 3 mm Hg/L/min. 7 It is hoped that these criteria will help in the much-needed identification of early pulmonary vascular disease. 8 As noninvasive testing is preferable to invasive measurements for the purposes of screening or initial diagnostic evaluation, an accurate and reproducible noninvasive measure of an individual s mppa-q relationship is desirable. Exercise echocardiography for the assessment of multipoint mppa-q relationships is feasible but technically challenging. 9,10 These technical demands limit the FOR EDITORIAL COMMENT SEE PAGE 876 application of exercise echocardiography to very few centers with sufficient expertise in this technique. Furthermore, the optimal exercise protocol for the assessment of the pulmonary circulation has not been established. 11 Dobutamine is an inochronotropic stress agent commonly used for the study of coronary artery disease 12 and offers potential advantages over exercise stress, as image acquisition is facilitated by reduced patient movement and cooperation with exercise is not required. Furthermore, studies in intact animals suggest that doses of dobutamine 20 m g/kg/min are without intrinsic vasomotor effects on the functional state of the pulmonary circulation. 13,14 The purpose of the present study was, therefore, to investigate the effects of an infusion of dobutamine on mppa-q relationships, as assessed by Doppler echocardiography in healthy volunteers and in patients with pulmonary arterial hypertension (PAH). We also compared the effects of exercise vs dobutamine stress on mppa-q relationships in the normal pulmonary circulation. Materials and Methods Subjects A total of 60 subjects participated in the study. Dobutamine stress echocardiography (DSE) was performed in healthy control subjects (n 5 22) and patients with PAH (n 5 16). An additional group of healthy control subjects (age- and sex-matched to the healthy control subjects who underwent DSE) who had undergone exercise echocardiography (n 522) were used as a comparison group to understand any differences in the mppa-q relationships during exercise vs dobutamine stress in the normal pulmonary circulation. Subjects in the exercise echocardiography group represented new analyses of previously reported studies. 9,15 A l l healthy control subjects were nonsmokers with no history of cardiac or respiratory diseases. All patients with PAH had their diagnosis confirmed by invasive, right-sided heart catheterization. The study was approved by the local institutional ethics review committees (Royal Prince Alfred Hospital Zone, RPAH-X ; Erasme University Hospital, P2011/101), and all participants provided informed consent. Stress Echocardiography Echocardiography images were acquired by either the Vivid system (General Electric Co) or ie33 (Koninklijke Philips NV). Dobutamine was given as a continuous infusion at incremental doses of 5, 10, 15, and a maximum of 20 m g/kg/min. Each infusion stage was for 3 min, and measurements for systolic pulmonary artery pressure (Ppa) and Q were taken during the last 30 s of each stage. The prespecified infusion end points were either reaching the maximum dobutamine dose or a heart rate (HR). 120 beats/min. A HR. 120 beats/min was chosen to avoid inducing very high HR in patients with PAH for safety reasons. Echocardiography data were recorded and analyzed offline by two independent observers. Exercise echocardiography was performed on a semirecumbent cycle ergometer (Model 900 EL; Ergoline GmbH), and workload was increased by 20 to 30 W every 2 min until the maximal tolerable workload, as previously described. 10 Systolic Ppa was measured from the peak tricuspid regurgitation jet. Right atrial pressure was assigned at 5 mm Hg for all healthy control subjects and estimated from the inferior vena cava diameter and collapsibility for patients with PAH. 16 The mppa was calculated as systolic Ppa An agitated air-blood-saline mixture was used to enhance the Doppler signal of the tricuspid regurgitation jet 18 from baseline through to peak stress in eight healthy control subjects in the dobutamine stress group. No subjects with PAH required agitated saline enhancement, as they all had sufficient tricuspid regurgitation jet. Q was estimated from the velocity time integral of the left ventricular outflow tract, together with HR and left ventricular outflow tract diameter. As no subjects had significant shunts present, total pulmonary vascular resistance (TPVR) was calculated as mppa/q. The interobserver variabilities of systolic Ppa and Q were determined to be 5.2% and 8.8%, respectively, for DSE. The interobserver variabilities of exercise stress echocardiography for systolic Ppa and Q were 7.9% and 13.9%, respectively. 10 Th e linearity of mppa-q curves was analyzed qualitatively and quantitatively. Linear regression was used to determine the slope 960 Original Research [ 146 # 4 CHEST OCTOBER 2014 ]

3 of best fit and intercept at zero flow. The pulmonary vascular distensibility coefficient a (percentage change in diameter per mm Hg increase in transmural pressure) was derived from each multipoint mppa-q plot by fitting into the following equation, as previously described 19 : where R 0 is the TPVR at rest ar0q [(1 alap) 5 ] 1 mppa a Statistical Analysis All data are presented as mean SD unless otherwise stated. Leastsquares linear regression was used to calculate the mppa-q slope. Between-group comparisons were made with one-way analysis of variance, and if significant differences were observed, subgroups were compared using independent samples t test analyses. Proportions were evaluated using the Fisher exact test. A Poon-adjusted mean slope was used to allow for similar linear or mildly nonlinear data from subjects to be grouped together for analyses. 20 A two-sided P,.05 was considered statistically significant. Results Baseline characteristics of the study groups are presented in Table 1. Two healthy control subjects and one patient with PAH who had undergone dobutamine stress were excluded from final analysis due to insufficient quality of echocardiographic measurements. The overall success rate for DSE was 93%. The diagnosis of patients with PAH included idiopathic PAH (n 5 6), connective tissue-associated PAH (n 5 9), and portopulmonary hypertension (n 5 1). Patients with PAH encompassed a range of disease severity. All TABLE 1 ] Baseline Characteristics of Study Subjects Characteristic Patients With PAH Dobutamine Stress (n 5 16) Dobutamine Stress (n 5 22) Control Subjects Exercise Stress (n 5 22) Age, y 56 9 a Male patients, % 25 b N/A Height, cm Weight, kg BMI, kg/m BSA, m Echocardiographic parameters LVEF, % 71 8 b ,.0001 TAPSE, mm 17 4 b ,.0001 Invasive hemodynamics c Systolic Ppa, mm Hg Diastolic Ppa, mm Hg 27 9 Mean Ppa, mm Hg Ppw, mm Hg 8 2 Mean RAP, mm Hg 9 5 NYHA functional class (No. in I:II:III:IV) P Value (2:6:7:1) 6-min walk distance, m PH-specific therapy Endothelin antagonist, % 75 Phosphodiesterase-5 inhibitor, % 56 Prostanoid, % 19 Combination therapy, % 44 Data given as mean (SD) unless otherwise indicated. BSA 5 body surface area; LVEF 5 left ventricular ejection fraction; N/A 5 not applicable; NYHA 5 New York Heart Association; PAH 5 pulmonary arterial hypertension; PH 5 pulmonary hypertension; Ppa 5 pulmonary artery pressure; Ppw 5 pulmonary artery wedge pressure; RAP 5 right atrial pressure; TAPSE 5 tricuspid annular plane systolic excursion. a P,.05 compared with exercise-stress control subjects. b P,.05 compared with dobutamine- and exercise-stress control subjects. c Invasive hemodynamics measured at time of initial diagnosis. journal.publications.chestnet.org 961

4 patients were receiving PH-specific therapy at the time of study. Hemodynamic Response to Dobutamine Infusion The peak dobutamine dose reached was similar for both control subjects and PAH groups ( mg/kg/min vs m g/kg/min), with an average of data points per multipoint mppa-q plot per subject. Resting and peak dobutamine hemodynamics are shown in Table 2. Resting Q was not significantly different between control subjects and patients with PAH, but peak Q was higher in control subjects ( L/min vs L/min, P 5.04) due to higher stroke volume at peak dobutamine dose (99 22 ml vs ml, P,.001). The HR and stroke volume responses during dobutamine infusion are shown in Figure 1. Dobutamine-Induced Multipoint mppa-q Relationships Th e average dobutamine-induced mppa-q slope in control subjects was mm Hg/L/min. After Poon adjustment, the slope of the best-fit line to pooled data was 1.0 mm Hg/L/min with an intercept of 10.7 mm Hg. At peak dobutamine, only one control subject had mppa. 30 mm Hg, occurring at a corresponding Q of 11.9 L/min. In the PAH group, the average mppa-q slope was mm Hg/L/min ( P,.001 vs control subjects), with a Poon-adjusted mppa-q slope of 4.8 mm Hg/L/min and an intercept of 27.3 mm Hg ( Fig 2 ). Using the curvilinear fit model, the average distensibility coefficient a was markedly reduced in patients with PAH compared with control subjects ( mm Hg vs mm Hg, P,.001). Within the PAH group, patients in New York Heart Association functional classes I or II had lower mppa-q slopes compared with those in functional classes III or IV ( mm Hg/L/min vs mm Hg/L/min, P 5.01), whereas resting TPVR was not associated with functional class status ( Fig 3 ). TABLE 2 ] Noninvasive Pulmonary and Systemic Hemodynamics at Rest and Peak Stress Measurement Condition Patients With PAH Dobutamine Stress (n 5 16) Dobutamine Stress (n 5 22) Control Subjects Exercise Stress (n 5 22) mppa, mm Hg Rest a ,.0001 P Value Peak stress a 20 4 b 35 6,.0001 Q, L/min Rest Peak stress a b ,.0001 Cardiac index, L/min/m 2 Rest Peak stress a b ,.0001 TPVR, dyn/s/cm 5 Rest a ,.0001 Peak stress a ,.0001 TPVRI, dyn/s/cm 5 /m 2 Rest 1, a ,.0001 Peak stress 1, a ,.0001 SBP, mm Hg Rest Peak stress b b ,.0001 DBP, mm Hg Rest Peak stress b b 94 6,.0001 HR, per min Rest a Peak stress a b ,.0001 RPP (SBP 3 HR) Rest 9,901 2,440 a 7,979 1,579 8,375 1, Peak stress 14,020 3,128 b 13,600 2,604 b 23,630 3,128,.0001 Data given as mean ( SD) unless otherwise indicated. DBP 5 diastolic BP; HR 5 heart rate; mppa 5 mean Ppa; Q 5 cardiac output; RPP 5 rate pressure product; SBP 5 systolic BP; TPVR 5 total pulmonary vascular resistance; TPVRI 5 total pulmonary vascular resistance index. See Table 1 legend for expansion of other abbreviation. a P,.05 compared with both dobutamine-stress control subjects and exercise-stress control subjects. b P,.05 compared with exercise-stress control subjects. 962 Original Research [ 146 # 4 CHEST OCTOBER 2014 ]

5 Figure 1 Hemodynamic response to incremental-dose dobutamine infusion in healthy control subjects and patients with PAH. A, Plot of mean (SD) values for heart rate. B, Plot of mean stroke volume values. *P,.05; **P,.01; ***P,.001. bpm 5 beats per min; PAH 5 pulmonary arterial hypertension. Dobutamine vs Exercise Stress in Healthy Control Subjects Baseline demographics and hemodynamics were well matched between the two healthy control groups who underwent exercise and dobutamine stress. Exercise stress achieved greater peak Q augmentation than dobutamine stress ( L/min vs L/min, P,.001). Compared with dobutamine stress, exercise stress was associated with a higher slope of the mppa-q relationship ( mm Hg/L/min vs mm Hg/L/min, P 5.03) and lower distensibility coefficient a ( mm Hg vs mm Hg, P 5.001). As exercise achieved significantly higher peak Q compared with dobutamine stress in healthy control subjects, a reanalysis of the exercise data were taken by limiting exercise Q to similar flow ranges achieved by peak dobutamine stress (exercise Qlimit L/min, P 5.6 vs peak dobutamine stress Q). This re-analysis enabled direct comparison between dobutamine and exercise stress over similar ranges of physiologic flows. This resulted in an exercise mppa-q slope of mm Hg/L/min ( P vs dobutamine stress) and a of /mm Hg ( P 5.06 vs dobutamine stress) (Fig 4 ). Discussion Our study demonstrates that it is feasible to derive meaningful mppa-q relationships using dobutamine stress to augment Q to assess the functional state of the pulmonary circulation. Subjects with PAH revealed markedly elevated mppa-q slopes compared with healthy control subjects under dobutamine stress. In addition, poor functional class status in patients with PAH was associated with higher dobutamine-induced mppa-q slopes. The novel application of DSE for the pulmonary circulation is a noninvasive technique that can potentially be applied to detect abnormal mppa-q responses from pulmonary vascular disease. Multipoint mppa-q Relationships The clinical utility of multipoint mppa-q assessment has previously been shown by Castelain et al 21 in a study on the hemodynamic effects of IV prostacyclin therapy in idiopathic PAH. Despite an increase in exercise capacity as assessed by 6-min walk distance at 6 weeks, resting TPVR remained unchanged, but the slope of the mppa-q relationship during exercise decreased significantly. Similarly, Provencher et al 22 demonstrated that changes in 6-min walk distance were associated with changes in exercise isoflow mppa but not resting measurements. Thus, there is accumulating evidence to suggest that the assessment of the pulmonary circulation under dynamic stress provides important clinical information in addition to resting measurements. This concept is supported by our finding that mppa-q slope, but not resting TPVR, correlated with functional class status in patients with PAH. Figure 2 A, Individual, dobutamineinduced, multipoint mppa and cardiac output (mppa-q) plots. B, Poon-adjusted pooled data of mppa-q relationships. The pooled mppa-q slope was 1.0 mm Hg/L/min with an intercept of 10.7 mm Hg in healthy control subjects and 4.8 mm Hg/L/min with an intercept of 27.3 mm Hg in patients with PAH. mppa 5 mean pulmonary artery pressure. See Figure 1 legend for expansion of other abbreviation. journal.publications.chestnet.org 963

6 Figure 3 A, B, Relationship between New York Heart Association FC status to mppa-q slope and resting TPVR in patients with PAH. Data shown are means and SD. FC was significantly associated with dobutamine-induced mppa-q slope ( mm Hg/L/min vs mm Hg/L/min for FC I-II vs FC III-IV, respectively; P 5.014). In comparison, FC status was not associated with resting TPVR ( P 5.13). FC 5 functional class; TPVR 5 total pulmonary vascular resistance. See Figure 1 and 2 legends for expansion of other abbreviations. Exercise vs Dobutamine Stress: Physiologic Considerations We compared the pulmonary hemodynamic response of exercise vs dobutamine stress in matched, healthy control subjects. As peak exercise can augment Q more than dobutamine stress, it is important that mppa-q relationships from exercise and dobutamine stress are compared over the same range of flows (approximately 5-10 L/min). In healthy control subjects, we found that dobutamine stress was associated with a lower mppa-q slope and a trend toward a higher distensibility coefficient a. This difference is most likely to be explained by dobutamine-induced pulmonary vasodilatation. Dobutamine has predominant b-adrenoceptor agonist activity, although lesser a-adrenorecptor effects do occur, particularly at higher doses. 23 Although previous studies suggest that dobutamine has minimal intrinsic Figure 4 Multipoint mppa-q plots at rest and during exercise stress (blue), and dobutamine stress (black) in healthy control subjects. Dobutamine- and exercise-induced mppa-q relationships were compared over similar physiologic flow ranges. The prediction bands of normal exercise response are shown in gray. See Figure 2 legend for expansion of abbreviations. effects on pulmonary vasomotor tone, these were performed in anesthetized animals with dobutamine doses generally less than those used in the present study. 13,14 Our more relevant human data would be in agreement with prior studies demonstrating a pulmonary vasoconstrictor response following sympathetic neural blockade in intact, conscious dogs. 24,25 The difference in mppa-q response between exercise and dobutamine stress could potentially be explained, alternatively, by exercise-induced vasoconstriction or exercise-related increase in Pla. However, we feel that these mechanisms are unlikely to be operational. By limiting the analysis of mppa-q relationships in the exercise group to the same flow ranges achieved by dobutamine infusion (peak Q of around 10 L/min), this corresponds to mild-moderate exercise workloads in healthy individuals. Significant exercise-induced vasoconstriction is unlikely to occur at this level of exercise. It has been shown that at Q of around 10 L/min, Pla changes little compared with resting values, but a brisker rise can occur at higher workloads when Q exceeds 20 L/min. 26 Finally, dobutamine should not significantly alter left ventricular filling pressures in subjects without coronary artery disease and with normal left ventricular function and normal baseline filling pressures Invasive exercise hemodynamic studies in patients with PAH have revealed mppa-q slopes ranging from 6 to 15 mm Hg/L/min, depending on the severity of the underlying pulmonary vascular disease. This is considerably higher than the mppa-q slopes found in our study. The comparative effects of dobutamine and exercise on mppa-q slopes were directly compared by Kafi et al 31 in an invasive study involving 11 patients with idiopathic PAH. In this study, the pooled, exerciseinduced mppa-q slope was 15 mm Hg/L/min vs a 964 Original Research [ 146 # 4 CHEST OCTOBER 2014 ]

7 dobutamine-induced mppa-q slope of 8.3 mm Hg/L/min. This supports the notion that dobutamine-induced mppa-q relationships result in a lower slope compared with exercise stress in patients with PAH, similar to the observations in the healthy control subjects. Apart from the likely effects of dobutamine-induced vasodilatation, pulmonary vasoconstriction can occur in patients with PAH even at relatively low workloads, due to early development of acidosis and decreased, mixed venous P o 2. Potential Utility of Dobutamine Stress for the Pulmonary Circulation The large reserve of the normal pulmonary circulation suggests that PAH is usually diagnosed late in its course and a latent (and relatively asymptomatic) stage precedes the onset of markedly reduced exercise capacity and right ventricular failure. 8 Thus, subjects with early PAH may present with normal or near-normal resting hemodynamics but an abnormal mppa response when stressed by an increase in pulmonary blood flow. 6,32 In our study, we demonstrated that subjects with established PAH had an average dobutamine-induced mppa-q slope of mm Hg/L/min compared with mm Hg/L/min in healthy control subjects. Furthermore, the dobutamine-induced distensibility coefficient a was markedly reduced in patients with PAH compared with control subjects ( vs /mm Hg). a derived from exercise echocardiography has been shown to be sensitive to subtle changes in pulmonary vascular function in asymptomatic carriers of BMPR2 mutations. 33 Further studies are required to determine whether dobutamine stress can reveal abnormal a and mppa-q response in at-risk populations who might have early pulmonary vascular disease but have not yet lost sufficient microvascular reserves to produce resting PAH (such as those with scleroderma disorders or carriers of BMPR2 mutations). Although dynamic exercise remains the most physiologic stressor as patient symptoms are replicated, the use of dobutamine as an alternative stressor of the pulmonary circulation has theoretical advantages. Exercise echocardiography requires very experienced echosonographers in dedicated centers and images must be acquired during the exercise, as pulmonary hemodynamics change rapidly once exercise is ceased. 10 Finally, analogous to stress testing for suspected coronary artery disease, exercise may not be feasible in patients with lower-limb musculoskeletal or neurologic diseases, and in those with suboptimal cooperation with exercise protocols. It is important to appreciate that mppa-q relationships generated by dobutamine and exercise stress may not be interchangeable, as suggested by the subtle differences in response found between the two stressors in the present study. Therefore, further validation studies in larger samples of healthy control subjects are required to determine the upper limits of normal for dobutamine-induced mppa-q relationships. Study Limitations It would be ideal to validate noninvasive mppa-q relationships against concurrent invasive measurements, but there is ethical concern regarding right-sided heart catheterization in healthy control subjects. We thus could not identify comparison data in the literature on invasively determined multipoint mppa-q relationships in healthy control subjects during incremental dobutamine infusion. The same control subjects were not subjected to both dobutamine and exercise stresses. However, the control groups were matched for age, sex, and BMI to reduce confounding factors. We cannot exclude that the difference in dobutamine- and exercise-stress response of the pulmonary circulation could be due to chance differences between the two control groups, but this appears unlikely. Furthermore, the PAH group was slightly older and tended toward a higher BMI compared with both control subjects. Although increasing age and possibly BMI are associated with higher mppa-q slopes,9,34 this would not have accounted for the marked differences observed. The present study was not large. It was designed as a proof-of-principle study to validate that DSE can be used for the study of the pulmonary circulation and can reveal the expected pathophysiologic abnormalities in those with established PAH. Future studies are required in healthy subjects over a larger age spectrum; in at-risk populations without resting PAH, such as asymptomatic carriers of BMPR2 mutations; and in those with cardiopulmonary conditions other than PAH. Conclusions By using dobutamine stress to augment pulmonary flow, multipoint mppa-q plots can be generated to noninvasively assess the functional status of the pulmonary circulation. This is potentially more prac tical than exercise stress echocardiography, and dobutamine stress reveals substantial differences between healthy subjects and those with PAH. Further validation studies are required to determine the potential utility of measuring mppa-q response during dobutamine stress for early diagnosis, prognostication, and monitoring of therapeutic response in PAH. journal.publications.chestnet.org 965

8 Acknowledgments Author contributions: E. M. T. L. served as principal author, had access to all of the data in the study, and takes responsibility for the integrity of the study data. E. M. T. L., L. R. S., T. J. C., R. N., and D. S. C. contributed to study concept and design; E. M. T. L., R. R. V., P. C., P. A., and M. D. contributed to data collection and analysis; R. N. and D. S. C. contributed to manuscript preparation; E. M. T. L. contributed to the drafting of the manuscript; R. R. V., P. C., L. R. S., T. J. C., P. A., and M. D. contributed to the review of the manuscript; and R. R. V., P. C., L. R. S., T. J. C., P. A., M. D., R. N., and D. S. C. contributed to the final approval of the manuscript. Financial/nonfinancial disclosures : The authors have reported to CHEST the following conflicts of interest: Dr Vanderpool reports receiving consulting fees from United Therapeutics Corp. Dr Corte has received an unrestricted educational grant for research from Actelion Pharmaceuticals Ltd. Drs Lau, Choudhary, Simmons, Argiento, D Alto, Naeije, and Celermajer have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Role of sponsors: The sponsors had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Other contributions: We acknowledge all echosonographers at Royal Prince Alfred Hospital for their technical assistance in the project. References 1. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J ;20(4): Lewis GD, Bossone E, Naeije R, et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation ;128(13): Naeije R, Chesler N. Pulmonary circulation at exercise. Compr Physiol ;2(1): Galiè N, Hoeper MM, Humbert M, et al ; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J ;30(20): Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation ;118(21): Kovacs G, Maier R, Aberer E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med ; 180 ( 9 ): Naeije R, Vanderpool R, Dhakal BP, et al. Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. Am J Respir Crit Care Med ;187(6): Lau EM, Manes A, Celermajer DS, Galiè N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J ;32(20): Argiento P, Vanderpool RR, Mulè M, et al. Exercise stress echocardiography of the pulmonary circulation: limits of normal and sex differences. Chest ;142(5): Argiento P, Chesler N, Mulè M, et al. Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J ;35(6): Bossone E, D Andrea A, D Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr ;26(1): Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol ;30(3): Pagnamenta A, Fesler P, Vandinivit A, Brimioulle S, Naeije R. Pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med ;31(4): Lejeune P, Naeije R, Leeman M, Melot C, Deloof T, Delcroix M. Effects of dopamine and dobutamine on hyperoxic and hypoxic pulmonary vascular tone in dogs. Am Rev Respir Dis ;136(1): Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol ;590(Pt 17 ): Milan A, Magnino C, Veglio F. Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics. J Am Soc Echocardiogr ;23(3): Chemla D, Castelain V, Humbert M, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest ;126(4): Jeon DS, Luo H, Iwami T, et al. The usefulness of a 10% air-10% blood-80% saline mixture for contrast echocardiography: Doppler measurement of pulmonary artery systolic pressure. J Am Coll Cardiol ;39(1): Linehan JH, Haworth ST, Nelin LD, Krenz GS, Dawson CA. A simple distensible vessel model for interpreting pulmonary vascular pressure-flow curves. J Appl Physiol (1985) ;73(3): Poon CS. Analysis of linear and mildly nonlinear relationships using pooled subject data. J Appl Physiol (1985) ;64(2): Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med ;165(3): Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J ;32(2): Langer SZ. Presence and physiological role of presynaptic inhibitory alpha 2-adrenoreceptors in guinea pig atria. Nature ;294(5842): Murray PA, Lodato RF, Michael JR. Neural antagonists modulate pulmonary vascular pressure-flow plots in conscious dogs. J Appl Physiol (1985) ;60(6): Naeije R, Lejeune P, Leeman M, Melot C, Closset J. Pulmonary vascular responses to surgical chemodenervation and chemical sympathectomy in dogs. J Appl Physiol (1985) ;66(1): Stickland MK, Welsh RC, Petersen SR, et al. Does fitness level modulate the cardiovascular hemodynamic response to exercise? J Appl Physiol (1985) ;100(6): Jewitt D, Birkhead J, Mitchell A, Dollery C. Clinical cardiovascular pharmacology of dobutamine. A selective inotropic catecholamine. Lancet ;2(7877): Parker JD, Landzberg JS, Bittl JA, Mirsky I, Colucci WS. Effects of betaadrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. Circulation ;84(3): el-said ES, Roelandt JR, Fioretti PM, et al. Abnormal left ventricular early diastolic filling during dobutamine stress Doppler echocardiography is a sensitive indicator of significant coronary artery disease. J Am Coll Cardiol ;24(7): Nakajima Y, Kane GC, McCully RB, Ommen SR, Pellikka PA. Left ventricular diastolic filling pressures during dobutamine stress echocardiography: relationship to symptoms and ischemia. J Am Soc Echocardiogr ; 22 ( 8 ): Kafi SA, Mélot C, Vachiéry JL, Brimioulle S, Naeije R. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol ;31(6): Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med ;179(2): Pavelescu A, Vanderpool R, Vachiéry JL, Grunig E, Naeije R. Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations. Eur Respir J ;40(5): Reeves JT, Dempsey JA, Grover RF. Pulmonary circulation during exercise. In: Weir EK, Reeves JT, eds. Pulmonary Vascular Physiology and Physiopathology. New York, NY : Marcel Dekker ; 1989 : Original Research [ 146 # 4 CHEST OCTOBER 2014 ]

Characterization of Patients With Borderline Pulmonary Arterial Pressure

Characterization of Patients With Borderline Pulmonary Arterial Pressure [ Original Research Pulmonary Vascular Disease ] Characterization of Patients With Borderline Pulmonary Arterial Pressure Gabor Kovacs, MD ; Alexander Avian, PhD ; Maria Tscherner, MD ; Vasile Foris, MD

More information

Exercise stress tests for detection and evaluation of pulmonary hypertension

Exercise stress tests for detection and evaluation of pulmonary hypertension European Heart Journal Supplements (2007) 9 (Supplement H), H17 H21 doi:10.1093/eurheartj/sum024 Exercise stress tests for detection and evaluation of pulmonary hypertension Sandrine Huez 1,2 * and Robert

More information

Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies

Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.

More information

Therapeutic Advances in Respiratory Disease. Original Research

Therapeutic Advances in Respiratory Disease. Original Research 573373TAR0010.1177/1753465815573373Therapeutic Advances in Respiratory DiseaseC Howard, K Rangajhavala research-article2015 Therapeutic Advances in Respiratory Disease Original Research Pulmonary artery

More information

THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU

THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU Cardiology Dept. Rambam Health Care Campus Rappaport Faculty of Medicine Technion, Israel Why the Right Ventricle? Pulmonary hypertension (PH) Right

More information

Right Heart Hemodynamics: Echo-Cath Discrepancies

Right Heart Hemodynamics: Echo-Cath Discrepancies Department of cardiac, thoracic and vascular sciences University of Padua, School of Medicine Padua, Italy Right Heart Hemodynamics: Echo-Cath Discrepancies Luigi P. Badano, MD, PhD, FESC, FACC **Dr. Badano

More information

Q: What is the best approach to a high systolic

Q: What is the best approach to a high systolic 1-MINUTE CONSULT BRIEF ANSWERS TO SPECIFIC CLINICAL QUESTIONS Approaches range from no further testing to right heart catheterization to referral MOSTAFA AHMED, MD Research Fellow, Department of Pulmonary,

More information

Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension

Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension ESC Congress 2011.No 85975 Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension Second Department of Internal

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

Nothing to Disclose. Severe Pulmonary Hypertension

Nothing to Disclose. Severe Pulmonary Hypertension Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis

More information

Assessing the Impact on the Right Ventricle

Assessing the Impact on the Right Ventricle Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal

More information

Resting pulmonary artery pressure of mmhg predicts abnormal exercise haemodynamics

Resting pulmonary artery pressure of mmhg predicts abnormal exercise haemodynamics ERJ Express. Published on March 1, 16 as doi: 1.1183/139933.1684-15 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Resting pulmonary artery pressure of 21 24 mmhg predicts abnormal exercise haemodynamics Edmund

More information

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring

Introduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained

More information

Hemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics

Hemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics Hemodynamic Assessment Matt M. Umland, RDCS, FASE Aurora Medical Group Milwaukee, WI Assessment of Systolic Function Doppler Hemodynamics Stroke Volume Cardiac Output Cardiac Index Tei Index/Index of myocardial

More information

Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden

Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden m.v.huisman@lumc.nl Background CETPH Chronic Thrombo Embolic Pulmonary Hypertension

More information

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms

More information

Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH

Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Javier Jimenez MD PhD FACC Director, Advanced Heart Failure and Pulmonary Hypertension Miami Cardiac & Vascular Institute

More information

Exercise-Induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology

Exercise-Induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology DOI: 10.1111/echo.12063 2012, Wiley Periodicals, Inc. Echocardiography Exercise-Induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology Rui Baptista, M.D.,*,

More information

Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan

Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan Original Article Acta Cardiol Sin 2017;33:498 509 doi: 10.6515/ACS20170612A Pulmonary Arterial Hypertension Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan

More information

Cardiovascular Images

Cardiovascular Images Cardiovascular Images Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography Brian C. Case, MD; Micheas Zemedkun, MD; Amarin Sangkharat, MD; Allen J. Taylor,

More information

Echo in Pulmonary HTN

Echo in Pulmonary HTN Echo in Pulmonary HTN Steven A. Goldstein MD FACC FASE Professor of Medicine Georgetown University Medical Center MedStar Heart Institute Washington Hospital Center Monday, October 10, 2017 Pulmonary Artery

More information

Disclosure. RV is not the innocent bystander 10/1/16. Assessment and Management of Pulmonary Heart Disease in the Female Patient

Disclosure. RV is not the innocent bystander 10/1/16. Assessment and Management of Pulmonary Heart Disease in the Female Patient Assessment and Management of Pulmonary Heart Disease in the Female Patient Oct 1, 2016 Deborah Women s Heart Center Susan E Wiegers, MD, FASE, FACC Professor of Medicine Senior Associate Dean of Faculty

More information

Echocardiographic assessment of pulmonary artery systolic pressure following treadmill stress testing

Echocardiographic assessment of pulmonary artery systolic pressure following treadmill stress testing European Heart Journal - Cardiovascular Imaging (2017) 18, 1278 1282 doi:101093/ehjci/jew308 Echocardiographic assessment of pulmonary artery systolic pressure following treadmill stress testing Arshad

More information

Real-world experience with riociguat in CTEPH

Real-world experience with riociguat in CTEPH Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International

More information

Journal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20.

Journal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20. Journal of the American College of Cardiology Vol. 33, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00055-8 Range

More information

Pulmonary Hypertension: Follow-up in adolescence and adults

Pulmonary Hypertension: Follow-up in adolescence and adults Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany

More information

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,

More information

P = 4V 2. IVC Dimensions 10/20/2014. Comprehensive Hemodynamic Evaluation by Doppler Echocardiography. The Simplified Bernoulli Equation

P = 4V 2. IVC Dimensions 10/20/2014. Comprehensive Hemodynamic Evaluation by Doppler Echocardiography. The Simplified Bernoulli Equation Comprehensive Hemodynamic Evaluation by Doppler Echocardiography Itzhak Kronzon, MD North Shore LIJ/ Lenox Hill Hospital New York, NY Disclosure: Philips Healthcare St. Jude Medical The Simplified Bernoulli

More information

Therapeutic approaches in P(A)H and the new ESC Guidelines

Therapeutic approaches in P(A)H and the new ESC Guidelines Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium

More information

Accuracy of echocardiography to evaluate pulmonary vascular and right

Accuracy of echocardiography to evaluate pulmonary vascular and right Accuracy of echocardiography to evaluate pulmonary vascular and right ventricular function during exercise Guido Claessen, MD 1, 2* ; Andre La Gerche, MD, PhD 1,3* ; Jens-Uwe Voigt, MD, PhD 1, 2 ; Steven

More information

What is controversial in diagnostic imaging?

What is controversial in diagnostic imaging? Controversies in the management of pulmonary hypertension What is controversial in diagnostic imaging? G. Derumeaux Lyon University Hospices Civils de Lyon France Déclaration de Relations Professionnelles

More information

The right heart: the Cinderella of heart failure

The right heart: the Cinderella of heart failure The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart

More information

The REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators

The REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial David M Kaye

More information

The Case of Lucia Nazzareno Galiè, M.D.

The Case of Lucia Nazzareno Galiè, M.D. The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical

More information

Pulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function. Irmina Gradus-Pizlo, MD

Pulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function. Irmina Gradus-Pizlo, MD Pulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function Irmina Gradus-Pizlo, MD Disclosures: Nothing to disclose Overview Is pulmonary hypertension

More information

Clinical implication of exercise pulmonary hypertension: when should we measure it?

Clinical implication of exercise pulmonary hypertension: when should we measure it? Clinical implication of exercise pulmonary hypertension: when should we measure it? Jang-Young, Kim Wonju College of Medicine, Yonsei Univ. Exercise pulmonary hypertension (EPH) Introduction of pulmonary

More information

Echo Doppler Assessment of Right and Left Ventricular Hemodynamics.

Echo Doppler Assessment of Right and Left Ventricular Hemodynamics. Echo Doppler Assessment of Right and Left Ventricular Hemodynamics. Itzhak Kronzon, MD, FASE, FACC, FESC, FAHA, FACP, FCCP Northwell, Lenox Hill Hospital, New York Professor of Cardiology Hofstra University

More information

Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan

Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose

More information

Cardiac Output (C.O.) Regulation of Cardiac Output

Cardiac Output (C.O.) Regulation of Cardiac Output Cardiac Output (C.O.) Is the volume of the blood pumped by each ventricle per minute (5 Litre) Stroke volume: Is the volume of the blood pumped by each ventricle per beat. Stroke volume = End diastolic

More information

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of

More information

DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES

DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES THORAXCENTRE DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES J. Roelandt DOPPLER HEMODYNAMICS Intracardiac pressures and pressure gradients Volumetric measurement

More information

The growing interest in pulmonary hypertension (PH) in

The growing interest in pulmonary hypertension (PH) in Eur Respir J 2010; 36: 986 990 DOI: 10.1183/09031936.00038410 CopyrightßERS 2010 EDITORIAL Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed N. Galiè, M. Palazzini and

More information

Quantitation of right ventricular dimensions and function

Quantitation of right ventricular dimensions and function SCCS Basics of cardiac assessment Quantitation of right ventricular dimensions and function Tomasz Kukulski, MD PhD Dept of Cardiology, Congenital Heart Disease and Electrotherapy Silesian Medical University

More information

Unexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M.

Unexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M. CHEST Unexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M. Redfield, MD Original Research PULMONARY HYPERTENSION Background: Idiopathic

More information

The Hemodynamics of PH Interpreting the numbers

The Hemodynamics of PH Interpreting the numbers The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado

More information

Right Ventricular Failure and Pulmonary Hypertension 2011

Right Ventricular Failure and Pulmonary Hypertension 2011 Right Ventricular Failure and Pulmonary Hypertension 2011 George G. Sokos, DO FACC Assistant Professor of Medicine, Temple University Director, Advanced Heart Failure and Cardiac Transplant Fellowship

More information

Right Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich

Right Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Pressure measurements Oxygen saturation measurements Cardiac output, Vascular

More information

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and

More information

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH Effectively treating patients with pulmonary hypertension: The next chapter Stuart Rich, M.D. Hemodynamic Progression of PAH Preclinical Symptomatic/ Stable Pulmonary Pressure Progressive/ Declining Level

More information

The Case of Marco Nazzareno Galiè, M.D.

The Case of Marco Nazzareno Galiè, M.D. The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical

More information

COMPLEX CONGENITAL HEART DISEASE: WHEN IS IT TOO LATE TO INTERVENE?

COMPLEX CONGENITAL HEART DISEASE: WHEN IS IT TOO LATE TO INTERVENE? COMPLEX CONGENITAL HEART DISEASE: WHEN IS IT TOO LATE TO INTERVENE? Aurora S. Gamponia, MD, FPPS, FPCC, FPSE OBJECTIVES Identify complex congenital heart disease at high risk or too late for intervention

More information

Pulmonary Hypertension: Another Use for Viagra

Pulmonary Hypertension: Another Use for Viagra Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A

More information

Evaluation of right atrial function using right atrial speckle tracking analysis in patients with pulmonary artery hypertension

Evaluation of right atrial function using right atrial speckle tracking analysis in patients with pulmonary artery hypertension J Echocardiogr (2016) 14:30 38 DOI 10.1007/s12574-015-0270-4 ORIGINAL INVESTIGATION Evaluation of right atrial function using right atrial speckle tracking analysis in patients with pulmonary artery hypertension

More information

HEMODYNAMIC ASSESSMENT

HEMODYNAMIC ASSESSMENT HEMODYNAMIC ASSESSMENT INTRODUCTION Conventionally hemodynamics were obtained by cardiac catheterization. It is possible to determine the same by echocardiography. Methods M-mode & 2D echo alone can provide

More information

Bosentan for treatment of pulmonary arterial hypertension (I)

Bosentan for treatment of pulmonary arterial hypertension (I) KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,

More information

The prevalence of atrial fibrillation (AF) increases

The prevalence of atrial fibrillation (AF) increases Long-term Prognostic Value of Dobutamine Stress Echocardiography in Patients With Atrial Fibrillation* Don Poldermans, MD; Jeroen J. Bax, MD; Abdou Elhendy, MD; Fabiola Sozzi, MD; Eric Boersma, PhD; Ian

More information

Pulmonary Arterial Hypertension and Obesity

Pulmonary Arterial Hypertension and Obesity 132 The Open Obesity Journal, 2010, 2, 132-136 Open Access Pulmonary Arterial Hypertension and Obesity Wendell H. Williams III 1, Robert E. Safford 2, Michael G. Heckman 3, Julia E. Crook 3 and Charles

More information

Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis

Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis Author's response to reviews Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis Authors: Mihai Strachinaru (m.strachinaru@erasmusmc.nl) Bas

More information

Pulmonary arterial hypertension (PAH) is a. How to detect disease progression in pulmonary arterial hypertension REVIEW

Pulmonary arterial hypertension (PAH) is a. How to detect disease progression in pulmonary arterial hypertension REVIEW Eur Respir Rev 212; 21: 123, 4 47 DOI: 1.1183/95918.911 CopyrightßERS 212 REVIEW How to detect disease progression in pulmonary arterial hypertension J-L. Vachiéry, P. Yerly and S. Huez ABSTRACT: Pulmonary

More information

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. 1. Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the

More information

Pulmonary arterial hypertension (PAH) is. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease REVIEW

Pulmonary arterial hypertension (PAH) is. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease REVIEW Eur Respir Rev 2011; 20: 122, 236 242 DOI: 10.1183/09059180.00006711 CopyrightßERS 2011 REVIEW Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease L.S. Howard ABSTRACT:

More information

Determination of Stroke Volume from Left Ventricular Isovolumetric Contraction and Ejection Times

Determination of Stroke Volume from Left Ventricular Isovolumetric Contraction and Ejection Times Determination of Stroke Volume from Left Ventricular Isovolumetric Contraction and Ejection Times Clarence M. AGRESS, M.D. and Stanley WEGNER SUMMARY Examination was made of the relationship of left ventricular

More information

Deleterious Effects of -Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension

Deleterious Effects of -Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension GASTROENTEROLOGY 2006;130:120 126 Deleterious Effects of -Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension STEEVE PROVENCHER,* PHILIPPE HERVE, XAVIER JAIS,* DIDIER

More information

Clinical Science Working Group 6: Diagnosis & Assessment of PAH. Co-chairs: David B. Badesch, MD Marius M. Hoeper, MD. Working Group 6 Members

Clinical Science Working Group 6: Diagnosis & Assessment of PAH. Co-chairs: David B. Badesch, MD Marius M. Hoeper, MD. Working Group 6 Members Clinical Science Working Group 6: Diagnosis & Assessment of PAH Co-chairs: David B. Badesch, MD Marius M. Hoeper, MD Working Group 6 Members Harm Jan Bogaard, Robin Condliffe, Robert Frantz, Dinesh Khanna,

More information

Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*

Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* CHEST Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* Anna Fijalkowska, MD; Marcin Kurzyna, MD; Adam Torbicki, MD; Grzegorz Szewczyk, MD; Michał

More information

The Doppler Examination. Katie Twomley, MD Wake Forest Baptist Health - Lexington

The Doppler Examination. Katie Twomley, MD Wake Forest Baptist Health - Lexington The Doppler Examination Katie Twomley, MD Wake Forest Baptist Health - Lexington OUTLINE Principles/Physics Use in valvular assessment Aortic stenosis (continuity equation) Aortic regurgitation (pressure

More information

The right ventricle in chronic heart failure

The right ventricle in chronic heart failure The right ventricle in chronic heart failure ESC 2012 Christian Opitz, Berlin There are no conflicts of interest relevant to this presentation Percent of Population Prevalence of Heart Failure by Age and

More information

To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure

To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose

More information

Mean Pulmonary Artery Pressure Using Echocardiography in Chronic Thromboembolic Pulmonary Hypertension

Mean Pulmonary Artery Pressure Using Echocardiography in Chronic Thromboembolic Pulmonary Hypertension Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Pulmonary Circulation Mean Pulmonary Artery Pressure Using Echocardiography in Chronic

More information

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have

More information

Elevated LV filling pressure is a major determinant of cardiac symptoms and

Elevated LV filling pressure is a major determinant of cardiac symptoms and LEFT VENTRICULAR FILLING PRESSURE, DIASTOLIC FUNCTION, AND HEART RATE PATRIZIO LANCELLOTTI, MD, PhD, FESC PERSPECTIVES Author affiliations: University of Liège hospital, GIGA Cardiovascular Science, Heart

More information

A NONINVASIVE METHOD FOR CHARACTERIZING VENTRICULAR DIASTOLIC FILLING DYNAMICS

A NONINVASIVE METHOD FOR CHARACTERIZING VENTRICULAR DIASTOLIC FILLING DYNAMICS A NONINVASIVE METHOD FOR CHARACTERIZING VENTRICULAR DIASTOLIC FILLING DYNAMICS R. Mukkamala, R. G. Mark, R. J. Cohen Haard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA Abstract We

More information

Exercise stroke volume and heart rate response differ in right and left heart failure

Exercise stroke volume and heart rate response differ in right and left heart failure European Journal of Heart Failure (2010) 12, 716 720 doi:10.1093/eurjhf/hfq062 Exercise stroke volume and heart rate response differ in right and left heart failure Herman Groepenhoff 1 *, Nico Westerhof

More information

Pulmonary arterial hypertension (PAH) is

Pulmonary arterial hypertension (PAH) is Eur Respir Rev 21; 19: 118, 314 32 DOI: 1.1183/95918.781 CopyrightßERS 21 REVIEW Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease

More information

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007 Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

PULMONARY HYPERTENSION

PULMONARY HYPERTENSION PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None

More information

Stress echo workshop STRESSORS

Stress echo workshop STRESSORS Stress echo workshop STRESSORS Adham Ahmed, MD Lecturer of Cardiology, Ain Shams Indications of Stress Echo CAD Diagnosis Prognosticat ion 1 Physiologic Basis 1930s: Tennant and Wiggers Relationship between

More information

Coronary artery disease (CAD) risk factors

Coronary artery disease (CAD) risk factors Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes

More information

Disclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension

Disclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension Disclosures A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension No financial relationships Susan P. D Anna MSN, APN BC, CHFN September 29, 2016 Objectives RV vs LV Differentiate

More information

Abstract ESC Pisa

Abstract ESC Pisa Abstract ESC 82441 Maximal left ventricular mass-to-power output: A novel index to assess left ventricular performance and to predict outcome in patients with advanced heart failure FL. Dini 1, D. Mele

More information

Echocardiographic Evaluation of Right Ventricular Function in Patients with Chronic Pre-Capillary Pulmonary Hypertension

Echocardiographic Evaluation of Right Ventricular Function in Patients with Chronic Pre-Capillary Pulmonary Hypertension Echocardiographic Evaluation of Right Ventricular Function in Patients with Chronic Pre-Capillary Pulmonary Hypertension Stefano Ghio, Laura Scelsi, Michele Pasotti, Giulia Magrini, Alessandra Serio, Lorenzo

More information

Incorporating the New Echo Guidelines Into Everyday Practice

Incorporating the New Echo Guidelines Into Everyday Practice Incorporating the New Echo Guidelines Into Everyday Practice Clinical Case RIGHT VENTRICULAR FAILURE Gustavo Restrepo MD President Elect Interamerican Society of Cardiology Director Fellowship Training

More information

Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension.

Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension. Echocardiographic assessment of the right ventricle in paediatric pulmonary hypertension. Mark K. Friedberg, MD No disclosures Outline RV response to increased afterload Echo assessment of RV function

More information

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts

More information

Pulmonary Hypertension. Echocardiography: Pearls & Pitfalls

Pulmonary Hypertension. Echocardiography: Pearls & Pitfalls Pulmonary Hypertension Echocardiography: Pearls & Pitfalls Αθανάσιος Γ. Κουτσάκης Ειδικευόμενος Καρδιολογίας Α Καρδιολογική Κλινική ΑΠΘ Σεμινάρια Ομάδων Εργασίας Ελληνικής Καρδιολογικής Εταιρείας Ιωάννινα,

More information

Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension

Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension CHEST Original Research PULMONARY VASCULAR DISEASE Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary Arterial Hypertension Malcolm M. Bersohn, MD, PhD ; Michelle P. Turner, MS ; Glenna L.

More information

Evaluation of Tissue Doppler Echocardiographic Imaging findings in children with pulmonary hypertension

Evaluation of Tissue Doppler Echocardiographic Imaging findings in children with pulmonary hypertension The Turkish Journal of Pediatrics 2017; 59: 244-253 DOI: 10.24953/turkjped.2017.03.003 Original Evaluation of Tissue Doppler Echocardiographic Imaging findings in children with pulmonary hypertension Alper

More information

Michigan Society of Echocardiography 30 th Year Jubilee

Michigan Society of Echocardiography 30 th Year Jubilee Michigan Society of Echocardiography 30 th Year Jubilee Stress Echocardiography in Valvular Heart Disease Moving Beyond CAD Karthik Ananthasubramaniam, MD FRCP (Glas) FACC FASE FASNC Associate Professor

More information

Response to questions at ACCA Webinar on Echocardiography in Critical Care

Response to questions at ACCA Webinar on Echocardiography in Critical Care Response to questions at ACCA Webinar on Echocardiography in Critical Care The participants in the Webinar were Bernard Cosyns [Professor of Cardiology at the Free University, Brussels, Belgium, and Chairman

More information

Prognostic Value of Left Ventricular Myocardial Performance Index in Patients Undergoing Coronary Artery Bypass Graft Surgery

Prognostic Value of Left Ventricular Myocardial Performance Index in Patients Undergoing Coronary Artery Bypass Graft Surgery Arch Iranian Med 2008; 11 (5): 497 501 Original Article Prognostic Value of Left Ventricular Myocardial Performance Index in Patients Undergoing Coronary Artery Bypass Graft Surgery Daryoosh Javidi MD

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed

More information

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling

More information

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &

More information

Stress Testing in Valvular Disease

Stress Testing in Valvular Disease 2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate

More information

Acute heart failure, beyond conventional treatment: persisting low output

Acute heart failure, beyond conventional treatment: persisting low output Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts

More information

Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency

Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Aim of haemodynamic monitoring in ICU and ED Detection and therapy of insufficient organ perfusion Answers to common cardiovascular

More information

Although idiopathic pulmonary arterial hypertension. Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines

Although idiopathic pulmonary arterial hypertension. Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines Prognosis of Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines Vallerie V. McLaughlin, MD, FCCP; Kenneth W. Presberg, MD, FCCP; Ramona L. Doyle, MD, FCCP; Steven H. Abman,

More information

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology Aortic Stenosis: UPDATE 2010 Anjan Sinha, MD Krannert Institute of Cardiology None Disclosures 67-Year-Old Male Dyspnea and angina Class III heart failure No PND or orthopnea 3/6 late peak SEM Diminished

More information

Comprehensive Hemodynamics By Doppler Echocardiography. The Echocardiographic Swan-Ganz Catheter.

Comprehensive Hemodynamics By Doppler Echocardiography. The Echocardiographic Swan-Ganz Catheter. Comprehensive Hemodynamics By Doppler Echocardiography. The Echocardiographic Swan-Ganz Catheter. Itzhak Kronzon, MD, FASE, FACC, FESC, FAHA, FACP, FCCP North Shore HS, LIJ/Lenox Hill Hospital, New York

More information